| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | NRX Pharmaceuticals, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| Di | Why Is NRx Pharmaceuticals Stock Falling After Data From Suicidal Bipolar Depression Study | 8 | Benzinga.com | ||
| Di | NRx Pharmaceuticals (Nasdaq:NRXP) Announces Promising Findings in Phase 2b/3 Clinical Trial of NRX-101 vs. Lurasidone for Treatment of Suicidal Bipolar Depression | 46 | PR Newswire | NRX-101 is first oral antidepressant to show 33% advantage in sustained remission in suicidality (not statistically significant at this sample size) and 75% advantage in relief from Akathisia relative... ► Artikel lesen | |
| Mo | NRX Pharmaceuticals, Inc. - 10-K/A, Annual Report | 5 | SEC Filings | ||
| 18.04. | Why Is NRX Pharmaceuticals (NRXP) Stock Down 29% Today? | 10 | InvestorPlace | ||
| 18.04. | NRx Pharmaceuticals, Inc.: NRx Pharmaceuticals (NASDAQ:NRXP) Receives Notice from Nasdaq that the Company has Demonstrated Compliance with the Bid Price Requirement | 87 | PR Newswire | The Nasdaq Panel has determined to continue the listing of the Company's securities on The Nasdaq Stock Market and is closing this matter
Four upcoming milestones expected: data from trials in Suicidal... ► Artikel lesen | |
| 17.04. | NRx Pharmaceuticals: New Data Demonstrates No Impact Of NRX-101 On Gut Or Vaginal Flora | 5 | RTTNews | ||
| 17.04. | NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics: Potential Implications for Avoidance of C. Difficile infections | 66 | PR Newswire | New data demonstrates no impact of NRX-101 on gut or vaginal flora - considered primary causes of pseudomembranous colitis due to C difficile and vaginal yeast infections
NRX-101 previously demonstrated... ► Artikel lesen | |
| 15.04. | NRX Pharmaceuticals, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
| 15.04. | (NRXP) - Analyzing NRX Pharmaceuticals' Short Interest | 9 | Benzinga.com | ||
| 15.04. | NRx Pharmaceuticals, Inc.: NRx Pharmaceuticals (NASDAQ:NRXP) Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine) | 89 | PR Newswire | Formulation based on prior patents by NRx founder
Achieved pH neutral formulation of ketamine, potentially enabling both intravenous (IV) and subcutaneous (SQ) administration
Company expects Composition... ► Artikel lesen | |
| 08.04. | NRx Pharmaceuticals, Inc.: NRx Pharmaceuticals (NASDAQ:NRXP) Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression | 80 | PR Newswire | Data transferred for independent statistical analysis
Top-line data expected in April 2024
RADNOR, Pa., April 8, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals"... ► Artikel lesen | |
| 02.04. | Earnings call: NRx Pharmaceuticals eyes ketamine alternative for depression | 15 | Investing.com | ||
| 01.04. | NRx Pharmaceuticals reports Q4 results | 4 | Seeking Alpha | ||
| 01.04. | NRx Pharmaceuticals, Inc.: NRx Pharmaceuticals (Nasdaq:NRXP) Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update | 169 | PR Newswire | Four potential near-term milestones, including data from two clinical trials, an NDA filing and an upcoming share dividend-- 50% reduction in corporate overhead and 25% reduction in overall net loss... ► Artikel lesen | |
| 29.03. | NRX Pharmaceuticals, Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
| 28.03. | NRX Pharmaceuticals, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 28.03. | NRx Pharmaceuticals reports Preliminary Q4 results and Full Year 2023 Financial Results | 4 | Seeking Alpha | ||
| 28.03. | NRx Pharmaceuticals, Inc.: NRx Pharmaceuticals (NASDAQ:NRXP) Reports Preliminary Fourth Quarter and Full Year 2023 Financial Results and Provides Year End Highlights | 86 | PR Newswire | Four potential near-term milestones, including data from two clinical trials, an NDA filing and a share dividend RADNOR, Pa., March 28, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)... ► Artikel lesen | |
| 28.03. | NRx Pharmaceuticals, Inc.: NRx Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing | 188 | PR Newswire | Common Stock Will Begin Trading on Split-Adjusted Basis on April 2, 2024
RADNOR, Pa., March 28, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company")... ► Artikel lesen |
Seite:
1 2 3 Weiter >>
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| EVOTEC | 3.335 |
| SUPER MICRO COMPUTER | 2.001 |
| AMAZON | 1.891 |
| MERCEDES-BENZ | 1.789 |
| DEUTSCHE BANK | 1.786 |
| TESLA | 1.782 |
| PAYPAL | 1.778 |
| NEL | 1.592 |
| NVIDIA | 1.377 |
| TUI | 1.312 |
| BYD | 1.302 |
| VOLKSWAGEN | 1.267 |
| BAYER | 1.183 |
| AMD | 881 |
| COMMERZBANK | 875 |
| VONOVIA | 760 |
| DEUTSCHE LUFTHANSA | 755 |
| CANOPY GROWTH | 719 |
| RWE | 684 |
| AIXTRON SE | 680 |
| BASF | 638 |
| RHEINMETALL | 635 |
| PLUG POWER | 590 |
| THYSSENKRUPP | 582 |
| META PLATFORMS | 571 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
